All Drug Development articles – Page 23
-
ArticleWomen in STEM with Charlotte Owens
As Senior Vice President and Head of Global Medical Affairs & Outcomes Research at the global healthcare company Organon, Charlotte Owen’s extensive work is advancing women’s healthcare and overcoming health inequities.
-
NewsNew two-step vaccination strategy for influenza
The novel strategy demonstrates a strong immune response, both body-wide and specifically in the upper respiratory tract, in porcine models.
-
ArticleThe art and science of drug formulation
Drug formulation is a cornerstone of modern medicine, turning raw active ingredients into consumable, effective therapies. This critical phase in drug development ensures that medications are safe, effective, and user-friendly. Here Ningfeng Fiona Li, founder and CEO of VasoDynamics, explores the world of drug formulation from its foundations to exploring ...
-
NewsType 1 regulatory cells limit immunotherapy success
Scientists discovered the number of Tr1 cells increased as tumours grew larger, making mice insensitive to immunotherapy.
-
ArticleOut of the lab and into patients: targeting APE1/Ref-1
We had the privilege of speaking to Dr Mark R. Kelley, Associate Director of Basic Science at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, and Betty and Earl Herr Professor in Pediatric Oncology Research, prior to his talk at PharmSci 360 in 2024. He elucidates what makes ...
-
ArticleShaping drug development success: how does artwork play a role?
Proactive approaches to labelling and artwork in preclinical stages of drug development reduce delays, minimise risk and expedite time to market.
-
ArticleAdvanced techniques in toxicity testing
Tune in to this episode where we explore how innovative assays and human-relevant cell models are transforming toxicity screening in drug development.
-
NewsSpinal muscular atrophy: searching for a cure
Organoids with SMA-pathology uncovered key findings about the disease, which could be utilised to develop new therapeutic options.
-
NewsMini-lungs enable breakthroughs in SARS-CoV-2 research
Researchers discovered two potential new drug applications with the possible clinical use of surfactant early in COVID-19 cases.
-
NewsDevelopment of a new and promising antimalarial agent
The new agent, DIF-1(+3), proved to be as effective against drug-resistant malaria as it was against susceptible strains.
-
ArticleTranslating ‘nature’s cues’ into breakthrough immunotherapies
Discover how Cue Biopharma harnesses the curative potential of the body’s intrinsic immune system to develop treatments for oncology and autoimmune diseases. Here, Anish Suri, Chief Scientific Officer of Cue Biopharma, explains how its platforms and biologics are designed to selectively modulate disease-specific T cells to restore immune balance, aiming ...
-
NewsTreating HCC with genetically modified NK-cell therapy
Blocking the TGF-β signalling pathway produced effective antitumour activity against hepatocellular carcinoma.
-
ArticleLiquid biopsy helps advance oncology drug development
In this exclusive interview with Elicio Therapeutics, we explore the transformative potential of liquid biopsy in oncology drug development, particularly spotlighting its application in Elicio’s AMPLIFY-201 study of ELI-002, a promising therapeutic cancer vaccine candidate.
-
NewsRare types of helper T cells uncovered
Researchers have created a new T cell atlas which could aid the development of novel drug therapies for immune-mediated diseases.
-
WebinarThe value of GPCR cell-based assays in drug discovery
Join this webinar to discover how GPCR functional, cell-based assays determine off-target effects, reveal safety issues, and define drug mechanism of action to ultimately evaluate the therapeutic potential of candidate molecules.
-
NewsNew ENaC blocker demonstrates an extended duration of action
The novel drug, ETD001, could provide an improved approach for mucus clearance in cystic fibrosis patients.
-
ArticleA T cell receptor immunotherapy against a novel target
In this Q&A, Associate Director, Research at Immunocore, Dr Ana Pereira Ribeiro, talks about IMC-R117C, a T cell receptor bispecific immunotherapy directed towards a novel target, PIWIL1, and about to enter Phase I testing in colorectal and gastrointestinal cancers.
-
ArticleeBook: Drop by drop: the future of liquid biopsy
The future of liquid biopsy is poised to revolutionise medical diagnostics and treatment. Explore the latest advancements and future prospects of liquid biopsy in our comprehensive eBook.
-
ArticleRecce Pharmaceuticals’ synthetic approach to combatting AMR
As antimicrobial resistance continues to advance, novel therapeutics are needed that stop infection and do not contribute to resistance. Australian biotech Recce Pharmaceuticals is paving the way for a new class of synthetic anti-infectives and providing hope for those with resistant infections. Recce’s lead candidate, RECCE® 327 (R327), is a ...
-
ArticleWomen in Stem with Dr Rachel Lagiakos
Dr H. Rachel Lagiakos is a Senior Principal Scientist in the Therapeutics Group at Schrödinger which she joined in 2018. She completed her PhD in Synthetic Organic Chemistry at Monash University and began her medicinal chemistry career at Cancer Therapeutics (CTx) in Melbourne, Australia in 2012. At CTx, Rachel’s contributions ...